Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report issued on Monday morning. The firm issued a hold rating on the stock.

Several other analysts also recently weighed in on ONCT. HC Wainwright dropped their price target on Oncternal Therapeutics from $19.00 to $18.00 and set a buy rating on the stock in a research note on Monday, August 12th. Brookline Capital Management reiterated a hold rating on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Northland Securities reiterated a market perform rating and issued a $2.00 price target on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Finally, Northland Capmk cut shares of Oncternal Therapeutics from a strong-buy rating to a hold rating in a research note on Thursday, September 12th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, Oncternal Therapeutics currently has a consensus rating of Hold and an average price target of $20.00.

Oncternal Therapeutics Stock Up 3.0 %

ONCT stock opened at $1.70 on Monday. The stock has a market capitalization of $5.03 million, a PE ratio of -0.14 and a beta of 1.39. Oncternal Therapeutics has a 52 week low of $1.32 and a 52 week high of $13.14. The firm has a 50 day moving average of $5.02 and a 200 day moving average of $7.29.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($2.89) EPS for the quarter, topping the consensus estimate of ($3.03) by $0.14. The business had revenue of $0.80 million during the quarter, compared to the consensus estimate of $0.24 million. Oncternal Therapeutics had a negative net margin of 1,948.70% and a negative return on equity of 136.10%. During the same period in the previous year, the firm posted ($3.00) earnings per share. On average, equities research analysts expect that Oncternal Therapeutics will post -11.4 earnings per share for the current year.

Institutional Trading of Oncternal Therapeutics

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Quantum Private Wealth LLC acquired a new position in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned approximately 0.94% of Oncternal Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.